Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - UroCor, Inc. (NasdaqNM:UCOR)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
Aug 28Price hit new 52-week high ($17.70)
July 25Conference call: UroCor Incorporated Earnings (Q2)
Location
840 Research Parkway
Oklahoma City, OK 73104
Phone: (405) 290-4000
Fax: (405) 290-4059
Email: irinfo@urocor.com
Employees (last reported count): 352
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Healthcare Facilities
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 48%
·Institutional: 70% (134% of float)
(64 institutions)
·Net Inst. Buying: 835.0K shares (+10.69%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
UroCor, Inc. markets a comprehensive range of products and services to assist in detecting, diagnosing, treating and managing prostate cancer, bladder cancer, kidney stones and other complex urologic disorders. The Company's primary focus is providing products and services to help urologists improve patient care and outcomes while reducing the total cost of managing these diseases. The Company provides comprehensive diagnostic services to detect major urologic conditions, enhance the accuracy of prognosis of individual patient's disease, monitor the patient's therapy and identify recurrence of the disease. UroCor also performs research and development work, pursuant to which it develops, evaluates and customizes new diagnostic products and technologies for use in its diagnostic service offerings. In addition, the Company facilitates the development and utilization of its disease databases and related information systems.
More from Market Guide: Expanded Business Description

Financial Summary
UCOR provides diagnostic services for the clinical management of certain urological cancers and diseases, and provides information services and therapeutic products to urologists and HMOs. For the six months ended 6/30/01, revenues increased 29% to $31.3 million. Net income rose from $865 thousand to $4.7 million. Revenues reflect the price increase on diagnostic services and the marketing of ProstaSeed. Earnings benefited from the gain on termination of therapeutic agrmt.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Herbert Conrad, 68
Chairman
--  
Michael George, 52
Pres, CEO, Director
$260K
Bruce Hayden, 40
CFO, Sr. VP, Sec., Treasurer
193K
Karl Nigg, 43
Sr. VP- Operations
205K
Melissa Walker, 39
VP, CCO
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:UCORAs of 31-Aug-2001
Price and Volume
52-Week Low
on 30-Nov-2000
$5.531
Recent Price$17.44 
52-Week High
on 28-Aug-2001
$17.70 
Beta0.56 
Daily Volume (3-month avg)166.6K
Daily Volume (10-day avg)66.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+179.0%
52-Week Change
relative to S&P500
+274.4%
Share-Related Items
Market Capitalization$174.1M
Shares Outstanding9.98M
Float5.20M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$4.07 
Earnings (ttm)-$0.13 
Earnings (mrq)$0.06 
Sales (ttm)$5.76 
Cash (mrq)$1.28 
Valuation Ratios
Price/Book (mrq)4.29 
Price/EarningsN/A 
Price/Sales (ttm)3.03 
Income Statements
Sales (ttm)$59.6M
EBITDA (ttm)-$1.12M
Income available to common (ttm)-$949.0K
Profitability
Profit Margin (ttm)-1.6%
Operating Margin (ttm)-6.8%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-1.93%
Return on Equity (ttm)-2.41%
Financial Strength
Current Ratio (mrq)4.97 
Debt/Equity (mrq)0.02 
Total Cash (mrq)$12.8M
Short Interest
As of 8-Aug-2001
Shares Short91.0K
Percent of Float1.8%
Shares Short
(Prior Month)
141.0K
Short Ratio0.51 
Daily Volume177.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.